These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 39144292)

  • 61. Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis.
    Yao Y; Li B; Song R; Yang L; Zou B; Wang L
    Radiat Oncol; 2024 Feb; 19(1):25. PubMed ID: 38413988
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of Real-world Efficacy and Safety of Atezolizumab and Durvalumab in Combination With Chemotherapy for First-line Treatment of Extensive-stage Small-cell Lung Cancer.
    Igata F; Inoue H; Ikeda T; Nakao A; Ebi N; Fujita M
    Anticancer Res; 2024 Jul; 44(7):3175-3183. PubMed ID: 38925816
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer.
    Xie Z; Liu J; Wu M; Wang X; Lu Y; Han C; Cong L; Li J; Meng X
    J Clin Med; 2023 Jun; 12(11):. PubMed ID: 37298023
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.
    Dou XJ; Ma RY; Ren DW; Liu Q; Yan P
    Lung Cancer (Auckl); 2024; 15():29-40. PubMed ID: 38560413
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report.
    Huang F; Tang J; Lou J; Wang Q; Ma K; Qiao R; Si J; Kang Y; Chen H; Mei J; Wang H; Liu Y; Miao L
    Transl Cancer Res; 2022 Sep; 11(9):3337-3342. PubMed ID: 36237231
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 68. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
    Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
    Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
    Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
    Wang Z; Zhao J; Ma Z; Cui J; Shu Y; Liu Z; Cheng Y; Leaw SJ; Wu Y; Ma Y; Tan W; Ma X; Zhang Y; Wang J
    Lung Cancer; 2020 Sep; 147():259-268. PubMed ID: 32769013
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
    Tomono H; Taniguchi H; Fukuda M; Ikeda T; Nagashima S; Akagi K; Ono S; Umeyama Y; Shimada M; Gyotoku H; Takemoto S; Hisamatsu Y; Morinaga R; Tagawa R; Ogata R; Dotsu Y; Senju H; Soda H; Nakatomi K; Hayashi F; Sugasaki N; Kinoshita A; Mukae H
    Thorac Cancer; 2023 Oct; 14(28):2890-2894. PubMed ID: 37675546
    [TBL] [Abstract][Full Text] [Related]  

  • 73. AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
    Zhao Y; Chen G; Chen J; Zhuang L; Du Y; Yu Q; Zhuang W; Zhao Y; Zhou M; Zhang W; Zhang Y; Wan Y; Li W; Song W; Wang ZM; Li B; Xia M; Yang Y; Fang W; Huang Y; Zhang L
    EClinicalMedicine; 2023 Aug; 62():102106. PubMed ID: 37593227
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Maintenance anlotinib improves the survival prognosis of extensive-stage small cell lung cancer: a single-arm, prospective, phase II study.
    Kong F; Wang Z; Wang N; Zhang D; Liao D; Zhang J; Sun Y; Zhang H; Jia Y
    Am J Cancer Res; 2023; 13(8):3679-3685. PubMed ID: 37693149
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
    Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
    BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.
    Wang L; Lei X; Wang X
    Comput Math Methods Med; 2022; 2022():2848220. PubMed ID: 35586668
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
    Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study.
    Lv XM; Liu Y; Feng Y; Liang HL; Zhi WW
    J Cancer; 2024; 15(11):3539-3546. PubMed ID: 38817880
    [No Abstract]   [Full Text] [Related]  

  • 79. Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer.
    Lu J; Lei X; Zhang P; Du L; Zhang Z; Qu B
    Cancer Med; 2023 Sep; 12(17):17924-17933. PubMed ID: 37563966
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study.
    Yuan J; Cheng F; Xiao G; Wang X; Fan H
    Front Oncol; 2022; 12():917089. PubMed ID: 35795060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.